Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study-Reference-Cited by-同舟云学术

Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study

Published:2020-10-23 Issue:4 Volume:192 Page:737-746
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Sharman Jeff¹²,Kabadi Shaum M.³,Clark Jamyia¹^ORCID,Andorsky David¹⁴^ORCID

Affiliation:

1. The US Oncology Network/McKesson Specialty Health Woodlands TX USA

2. Willamette Valley Cancer Institute and Research Center Eugene OR USA

3. AstraZeneca Wilmington DE USA

4. Rocky Mountain Cancer Centers Boulder CO USA

Funder

AstraZeneca Canada

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16922

Reference19 articles.

1. Leukemia and Lymphoma Society.Mantle Cell Lymphoma Facts[Internet].2019[updated 1 November 2019]. Available from:http://www.lls.org/sites/default/files/file_assets/FS4_MCL_Facts_Rev.pdf. accessed July 20 2020

2. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

3. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

4. NCCN Clinical Practice Guidelines in Oncology.B‐Cell Lymphomas. Version 2.2020 [Internet]. 2020 [updated 9 July 2020]. Available from:http://www.nccn.org/professionals/physician_gls/pdf/b‐cell.pdfaccessed July 20 2018.

5. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review;Journal of Blood Medicine;2024-05

3. Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia;Cancer Medicine;2024-01

4. Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia;Leukemia & Lymphoma;2023-10-23

5. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs;Leukemia & Lymphoma;2023-07-27